Table 1.
Selected clinical trials of trastuzumab in gastro-esophageal cancer
| Ref. | Phase | Treatment | n | OS (mo) | PFS (mo) | RR | CR | PR |
| Bang et al[73] | III | 5-FU + cisplatin or capecitabine + cisplatin | 290 | 11.1 | 5.5 | 34.50% | NA | NA |
| Trastuzumab + 5-FU + cisplatin or trastuzumab + capecitabine + cisplatin | 294 | 13.8 | 6.7 | 47.30% | NA | NA | ||
| Cortés-Funes et al[67] | II | Trastuzumab + cisplatin | 21 | NA | NA | 41.10% | 5.80% | 35.00% |
| Egamberdiev et al[68] | II | Trastuzumab + leucovirin + cisplatin + 5-FU | 16 | NA | 8.3 | 54.50% | NA | NA |
| Leucovirin + cisplatin + 5-FU | 18 | NA | 5.2 | 33.30% | NA | NA | ||
| Grávalos et al[69] | II | Trastuzumab + cisplatin | 22 | NA | 5.1 | 32.00% | NA | NA |
OS: Overall survival; PFS: Progression-free survival; 5-FU: 5-fluorouracil; RR: Response rate; CR: Complete response; PR: Partial response; NA: Not available.